drugset
drugset / Trial / NCT04918628

Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical Cancer

NCT04918628 ↗

Phase 2 Unknown 50 enrolled Taizhou Hospital
NaSingle-groupOpen-labelTreatment

Summary

This phase II study is to Evaluate the Safety and Efficacy of Neoadjuvant Chemotherapy Combined With CCRT Followed by Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical Cancer.（ CRTCP）

Timeline

Start
2021-05-01
Primary completion
2023-06-01
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

cervical cancer